Protagonist Therapeutics Inc Conference Call to Discuss its Agreement with Janssen Biotech, Inc to Co-Develop and Commercialize

30/5/2017 8:00

Llamada en conferencia Protagonist Therapeutics Inc

Protagonist Therapeutics Inc Conference call or earnings call will be held on 30-may-2017 During the earnings conference call's session Protagonist Therapeutics Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conference call the bridge access number and key in the PIN code, Contact Protagonist Therapeutics Inc for this information
Schedule a conference call with QCONF and get 5 free conference calls.
We are a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities ("NCEs" ) to address significant unmet medical needs. Our primary focus is on developing first-in-class oral peptide drugs that specifically target the same biological pathways also targeted by currently marketed injectable antibody drugs. Compared to injectable antibody drugs, our oral peptides offer targeted delivery to the gastrointestinal ("GI") tissue compartment, potential for improved safety due to minimal exposure in the blood, improved convenience and compliance due to oral delivery and the opportunity for earlier introduction of targeted therapy for inflammatory bowel disease ("IBD").    
Leer más Llamada en conferencia

Protagonist Therapeutics Inc (PTGX)

521 Cottonwood Drive, Milpitas California 95035, United States